ACCESS: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
Sponsor: |
NMDP |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAT7521 |
U.S. Govt. ID: |
NCT04904588 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to see how well an allogenic transplant works in adults with an MMUD using stem cells from a donor's blood (instead of using the donor's bone marrow). An allogeneic stem cell transplant is a standard treatment for blood cancers. An allogeneic transplant replaces your abnormal (or diseased) blood cells with healthy blood-making cells from a donor. We're doing this study to see how well transplant works in adults with an MMUD using stem cells from a donor's blood. This study treatment does not include any investigational drugs.
This study is closed
Investigator
Ran Reshef, MD
Are you at least 18 years old? |
Yes |
No |
Have you been diagnosed with multiple myeloma, leukemia, or lymphoma? |
Yes |
No |
Is your liver functional? |
Yes |
No |